乾燥粉末吸入器（DPI）市場：製品タイプ、用途、販売チャネル、地域別、2026～2032年

乾燥粉末吸入器（DPI）市場の評価-2026～2032年

慢性呼吸器疾患の有病率の増加、DPIの技術開発、セルフメディケーション志向の高まりなどが市場の急拡大に寄与しています。Verified Market Researchのアナリストによると、乾燥粉末吸入器市場は、2024年には約184億米ドルの評価額を下回り、予測期間中に244億7,000万米ドルの評価額に達すると推定されます。

呼吸器疾患の割合の増加、DPIデバイス技術の向上、迅速かつ効率的な吸入治療に対する患者の需要などが、乾燥粉末吸入器（DPI）市場の力強い拡大に寄与しています。これに基づき、市場は2026～2032年までCAGR 3.6％で成長します。

乾燥粉末吸入器（DPI）市場：定義/概要

乾燥粉末吸入器（DPI）は、乾燥粉末の形で肺に薬剤を投与する医療機器です。推進剤を利用して薬剤を吐出する通常の吸入器とは異なり、DPIは患者の呼吸を利用して粉末を吸入します。気管支拡大剤、コルチコステロイド、その他の薬剤を呼吸器に直接投与する便利で効果的な方法を提供するため、喘息、慢性閉塞性肺疾患（COPD）、その他の肺疾患などの呼吸器疾患の治療に広く使用されています。

DPI市場の成長軌道を形成する主要促進要因は？

慢性閉塞性肺疾患（COPD）、喘息、嚢胞性線維症などの呼吸器疾患の有病率の上昇は、DPI市場の重要な促進要因です。同様に、Global Asthma Report 2018では、喘息は世界で3億3,900万人以上が罹患していると予測しています。吸入療法を必要とする患者数の拡大が、効果的で利便性の高いDPIデバイスの需要を促進しています。

DPIは、標準的な定量吸入器（MDI）やネブライザーと比較して、携帯性、使用の利便性、推進剤の排除など、さまざまな利点があります。これらの利点により、DPIは患者にとってより魅力的なものとなり、その結果、より高い普及率が得られます。Journal of Aerosol Medicine and Pulmonary Drug Delivery誌（2019年）に掲載された調査によると、患者の89％が、その使いやすさと可動性から、定量吸入器よりもDPIを好みました。

国連によると、世界の人口は高齢化しており、60歳以上の人口は2050年までに倍増すると予想されています。高齢者は呼吸器感染症にかかりやすく、このような患者層にとってより使いやすく、より効果的なDPIデバイスの需要が高まっています。

さらに、DPI装置の設計、薬剤の配合、製造プロセスにおける絶え間ない進歩が、これらの製品の効率と使用を向上させています。例えば、多回投与DPIや呼吸作動式DPIの開発により、患者のコンプライアンスと利便性が向上しました。例えば、BMJオープンに掲載された研究によると、英国では定量吸入器（MDI）の10％を乾燥粉末吸入器（DPI）に切り替えることで、年間5万8,000トンの二酸化炭素排出量を削減できるといいます。

乾燥粉末吸入器（DPI）市場で企業が直面する課題とは？

DPIで効果的な薬剤送達を行うには適切な吸入方法が不可欠ですが、これは小さな幼児や高齢者、協調性に問題のある患者にとっては難しいことです。呼吸方法が一定でないと、肺への薬剤の蓄積が少なくなり、治療効果が損なわれる可能性があります。

安定した効果的なDPI製剤を作るのは難しいです。粉末は効率的な吸入のために十分微細でなければならず、同時に最適な分散のために適切な流動特性を持たなければならないです。さらに、薬剤によっては吸湿性があり、周囲から湿気を蓄積し、DPI内での安定性や機能に影響を及ぼすものもあります。

さらに，DPIは，加圧式定量吸入器（MDI）やネブライザーなどの他の吸入技術と競合しています。MDIはその使いやすさから推奨されているのに対し、ネブライザーは吸入技術に悩む人や高用量の薬を必要とする人に適しているため、特定のセグメントにおけるDPIの市場成長が制限されています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 乾燥粉末吸入器（DPI）市場：剤形別

• 副腎皮質ステロイド
• 気管支拡大薬
• 抗生物質
• 配合剤

第5章 乾燥粉末吸入器（DPI）市場：地域別

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• その他

第6章 乾燥粉末吸入器（DPI）市場：用途別

• 喘息
• 慢性閉塞性肺疾患（COPD）
• 嚢胞性線維症
• その他の呼吸器疾患

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Merck & Co., Inc.
• 3M Pharmaceuticals
• Hovione
• MannKind Corpo

第11章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 供給源と参考文献

Dry Powder Inhaler (DPI) Market Valuation - 2026-2032

The increasing prevalence of chronic respiratory diseases, technological developments in DPIs, and the growing inclination towards self-medication are all contributing to the market's rapid expansion. According to the analyst from Verified Market Research, the dry powder inhaler market is estimated to reach a valuation of USD 24.47 Billion over the forecast subjugating around USD 18.4 Billion valued in 2024.

The growing rates of respiratory illnesses, improved DPI device technology, and patient demand for quick and efficient inhalation treatment are all contributing to the market's strong expansion for dry powder inhalers, or DPIs. It enables the market to grow at a CAGR of 3.6% from 2026 to 2032.

Dry Powder Inhaler (DPI) Market: Definition/ Overview

A Dry Powder Inhaler (DPI) is a medical device that administers medication to the lungs in the form of dry powder. Unlike regular inhalers, which utilize a propellant to dispense medication, DPIs use the patient's breath to inhale the powder. These devices are widely used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases, as they provide a convenient and effective way to deliver bronchodilators, corticosteroids, and other medications directly to the respiratory tract.

What are the Key Drivers Shaping the Growth Trajectory of the DPI Market?

The rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis is a significant driver of the DPI market. Similarly, the Global Asthma Report 2018 predicts that asthma affects more than 339 million individuals worldwide. The expanding number of patients requiring inhalation therapy is driving the demand for effective and convenient DPI devices.

DPIs have various advantages over standard metered-dose inhalers (MDIs) and nebulizers, including portability, convenience of use, and the elimination of propellants. These advantages make DPIs more enticing to patients, resulting in higher adoption. According to research published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery (2019), 89% of patients preferred DPIs to metered-dose inhalers because of their ease of use and mobility.

The global population is aging, with the number of individuals aged 60 and older anticipated to double by 2050, according to the United Nations. Older persons are more vulnerable to respiratory infections, increasing the demand for DPI devices that are simpler to use and more effective for this patient population.

Furthermore, continuous advancements in DPI device design, medication formulations, and manufacturing processes improve the efficiency and use of these products. For example, the development of multi-dose DPIs and breath-actuated DPIs has increased patient compliance and convenience. For instance, according to a study published in BMJ Open, switching 10% of metered-dose inhalers (MDIs) to dry powder inhalers (DPIs) in the UK could reduce carbon emissions by 58,000 tons annually.

What are the Challenges Faced by Companies in the Dry Powder Inhaler (DPI) Market?

Proper inhaling methods are essential for effective medication delivery with a DPI, which can be challenging for small children, elderly patients, and individuals with coordination issues. Inconsistent breathing procedures cause less medication accumulation in the lungs, potentially jeopardizing therapy efficacy.

Creating stable and effective DPI compounds is difficult. The powder should be fine enough for efficient inhalation while also having appropriate flow characteristics for optimum dispersion. Furthermore, some drugs are hygroscopic, accumulating moisture from their surroundings, affecting their stability and function within a DPI.

Furthermore, DPIs compete with other inhalation technologies, such as pressurized metered dosage inhalers (MDIs) and nebulizers. MDIs are recommended for their ease of use, whereas nebulizers are appropriate for people suffering from inhalation techniques or requiring high medicine doses, which limits market growth for DPIs in certain segments.

Category-Wise Acumens

How Does the Dominance of Capsule-based DPIs Contribute to the Overall Market?

According to VMR Analysis, the capsule-based segment is estimated to hold the largest market share during the forecast period. Capsule-based DPIs are designed to be simple and user-friendly for patients. They frequently have a simple loading mechanism that requires little effort to prepare the dose. Furthermore, capsule-based devices are small and lightweight, which improves portability and convenience for patients on the move.

Capsule-based DPIs provide better dosage precision than other device types. The pre-metered capsules ensure that each dose includes the exact amount of medication, reducing the risk of under- or overdosing. This precision contributes to improved therapeutic efficacy and patient outcomes.

Furthermore, DPI capsules work well with a wide range of respiratory drugs, including bronchodilators, corticosteroids, and combination therapy. This adaptability enables healthcare providers to modify treatment strategies to particular patient demands, resulting in the widespread use of capsule-based devices.

What Drivers Support the Maximum Usage of DPI in Treating COPD?

The chronic obstructive pulmonary disease (COPD) segment is estimated to dominate the dry powder inhaler market during the forecast period. COPD is a prominent cause of illness and mortality worldwide, with a large and increasing prevalence. The World Health Organization estimates that over 65 million people suffer from COPD globally. This vast patient population creates a demand for effective inhalation medicines for COPD therapy, such as DPIs.

COPD is primarily controlled with inhalation medicines, which effectively deliver pharmaceuticals to the lungs. DPIs have been a popular alternative among COPD patients due to their portability, convenience, and ability to administer exact medicine doses precisely to the afflicted parts of the respiratory system.

Additionally, there is an increasing emphasis on preventative healthcare strategies for respiratory disorders such as COPD. DPIs serve an important role in providing targeted drug delivery, reducing exacerbations, and improving overall health outcomes for COPD patients, which has fueled their acceptance in this segment.

Country/Region-wise Acumens

What Unique Market Dynamics Contribute to North America's Leadership in the Market?

According to VMR Analyst, North America is estimated to dominate the dry powder inhaler market during the forecast period. Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory disorders in North America, particularly in the United States. According to the Centers for Disease Control and Prevention, more than 25 million Americans have asthma, while an estimated 16 million people in the United States suffer from COPD. This vast patient population increases the demand for effective inhalation medicines such as DPIs.

North America, led by the United States, has a well-developed healthcare system that provides extensive access to innovative medical technologies and treatments. This allows for the adoption of innovative DPI equipment and promotes the growth of the DPI market in the region. The presence of important market participants, as well as ongoing R&D initiatives, contribute to the region's dominant position.

Furthermore, the availability of favorable payment rules for respiratory drugs and equipment increases patient access to DPIs. This, combined with the population's strong spending power, makes North America an appealing market for DPI producers, driving overall regional market growth.

What Factors Lead to Asia Pacific Experiencing the Fastest Growth in the Market?

The Asia Pacific region is estimated to exhibit the highest growth within the dry powder inhaler market during the forecast period. The Asia-Pacific region includes a sizable and expanding patient population suffering from respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. According to the Global Asthma Report 2018, the Asia-Pacific region has the most people with asthma, accounting for more than 175 million cases. This high illness burden drives the region's adoption of effective inhalation medicines such as DPIs.

Governments in the Asia-Pacific region are boosting their investments in healthcare access and infrastructure, particularly in emerging countries. This, together with increased awareness of respiratory disorders and the benefits of sophisticated inhalation devices among healthcare professionals and patients, is driving the DPI market in this region.

Furthermore, leading multinational pharmaceutical and medical device businesses are increasing their presence and manufacturing capabilities in Asia-Pacific to meet rising demand. Also, strategic collaborations between major corporations and local players are permitting the launch of innovative DPI products adapted to the needs of the regional market, which is driving the Asia-Pacific DPI market forward.

Competitive Landscape

The dry powder inhaler (DPI) market is characterized by fierce competition among leading competitors, which is driven by ongoing innovation and developments in device technology. Additionally, the rising prevalence of respiratory disorders has prompted significant investment in R&D, resulting in the launch of new formulations and combination medicines.

Some of the prominent players operating in the dry powder inhaler (DPI) market include:

GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., 3M Pharmaceuticals, Hovione, MannKind Corpo.

Latest Developments

In February 2021, Catalent Inc. purchased Acorda Therapeutics Inc., expanding its DPI production capabilities and adding a commercial-stage pharmaceutical to its portfolio. This acquisition highlights the growing importance of DPI treatments in respiratory and neurological illnesses.

In April 2019, Hovione Technology acquired the rights to develop and commercialize Dr. Klaus-Dieter Beller's Papillon DPI, a revolutionary and cost-effective dry powder inhaler technology.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Dry Powder Inhaler (DPI) Market, By Formulation

• Corticosteroids
• Bronchodilators
• Antibiotics
• Combination products

5. Dry Powder Inhaler (DPI) Market, By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World

6. Dry Powder Inhaler (DPI) Market, By Application

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Other respiratory conditions

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Merck & Co., Inc.
• 3M Pharmaceuticals
• Hovione
• MannKind Corpo

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References